$CYTH News

Last published 1y ago

1y agoCYTH RFLRafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder ApprovalsGlobeNewswireNEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced the closing of their business combination following
1y agoCYTH RFLRafael Holdings Reports Second Quarter Fiscal 2025 Financial ResultsGlobeNewswireThe planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo's lead clinical program
1y agoCYTHCyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)Business WireFirst data in NPC1 on treatment in this age group over a period of 48 weeks At 24 weeks of the sub-study, 7 of 8 patients (87%) and at 48 weeks of the sub-study, 6 of 7 patients (86%) show stabilization or improvement
1y agoCYTHCyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025Business WirePivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") to be highlighted in an oral presentation Cyclo Therapeutics, Inc. (NASDAQ:CYTH)
1y agoARCH CYTH FLIC USAPKuehn Law Encourages USAP, CYTH, ARCH, and FLIC Investors to Contact Law FirmGlobeNewswireNEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
1y agoCYTH RFLRafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsGlobeNewswireNEWARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the first quarter of fiscal year 2025 ended October 31, 2024. "We anticipate proceeding to a
1y agoCYTHCyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness WireStrategic merger with Rafael Holdings to combine two companies and advance Trappsol® Cyclo™ for NPC1 patients expected to close Q4 2024 Company on track for topline data from the 48-week interim analysis
2y agoCYTH RFLRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsGlobeNewswireNEWARK, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the fourth quarter and the full fiscal year ended July 31, 2024. "During fiscal 2024, we
2y agoCYTH PCRXPacira BioSciences Appoints Shawn Cross as Chief Financial OfficerGlobeNewswireTAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the appointment of Shawn Cross as
2y agoCYTHCyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)Business WireTwo posters presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 Pivotal TransportNPC™ study is the most comprehensive ongoing controlled pivotal study regarding
2y agoCYTH ARCH CEIX VGRKuehn Law Encourages CYTH, ARCH, CEIX, and VGR Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
2y agoCYTH RFLRafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger AgreementBusiness WireCyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from
2y agoCYTH RFLRafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger AgreementGlobeNewswireCyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the
2y agoCYTHCyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateBusiness WireQuarter marked by achievement of landmark milestone with completion of enrollment in pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type
2y agoCYTHCyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent OfficeBusiness WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
2y agoCYTHCyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024Business WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
2y agoCYTH RFLRafael Holdings Reports Third Quarter Fiscal 2024 Financial ResultsGlobeNewswireNEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. "During
2y agoCYTH RFLCyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1Business WireTransportNPC™ is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for the treatment of Niemann-Pick Disease Type C1 (NPC1) Topline
2y agoCYTHCyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness WireOngoing progress toward last patient enrolled in pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2
2y agoCYTHCyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateBusiness WireContinued progress of pivotal Phase 3 study (TransportNPC™) evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) toward 48-week comparative interim analysis data
2y agoCYTHCyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's DiseaseBusiness WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
2y agoCYTH RFLRafael Holdings Reports Second Quarter Fiscal 2024 Financial ResultsGlobeNewswireCompany remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Increased ownership in Day Three Labs to a majority interest of 79%
2y agoCYTHCyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark OfficeBusiness WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
2y agoAMTI CYTHCyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.Business WireCombined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with
2y agoCYTHCyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1Business WireOngoing pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) FDA feedback provides direction for the comparative interim
2y agoCYTH RFLRafael Holdings Reports First Quarter Fiscal 2024 Financial ResultsGlobeNewswireNEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023. "During fiscal
2y agoCYTHCyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024Business WirePivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") to be highlighted in a platform presentation Cyclo Therapeutics, Inc. (NASDAQ:CYTH)
2y agoAMTI CYTH RFLCyclo Therapeutics Reports Third Quarter 2023 Financial ResultsBusiness WireStrong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") Merger with Applied Molecular Transport,
3y agoCYTH RFLRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial ResultsGlobeNewswireNEWARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the fourth quarter and full year of fiscal 2023 - the three and twelve months ended July 31,
3y agoCYTHCyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 MillionBusiness WireIssues New Warrants to this Investment Group for Possible Additional Funding of Up to $3.47 Million (if exercised) Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage
3y agoCYTHCyclo Therapeutics to Present at 8th Annual Dawson James ConferenceBusiness WireLive webcast presentation on Thursday, October 12th at 12:00 PM ET Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing
3y agoAMTI CYTHCyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger AgreementBusiness WireCombined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have
3y agoCYTH RFLCyclo Therapeutics Reports Second Quarter 2023 Financial ResultsBusiness WireContinued strong enrollment of pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) on track to complete enrollment by year end
3y agoCYTH RFLCyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.Business WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
3y agoCYTHCyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1Business Wire– Data published in official journal of Molecular Genetics and Metabolism Reports: Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion Trappsol®
3y agoCYTHCyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's DiseaseBusiness WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
3y agoCYTH RFLCyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private PlacementBusiness WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
3y agoCYTH RFLCyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsBusiness WireCompany on track to complete enrollment in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) by year end 2023 Cyclo
3y agoCYTH RFLCyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)Business WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
3y agoCYTHCyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq RulesBusiness WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
3y agoCYTHCyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial ResultsBusiness WirePivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) projected 40% enrolled by the end of March; Company on track to complete enrollment by
3y agoCYTHCyclo Therapeutics Provides Clinical Program Update and Highlights Recent AchievementsBusiness WireContinued progress in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) with 35% of expected enrollment completed, on track to
3y agoCYTHCyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch EventBusiness WireLive video webcast on Thursday, January 19th at 11:00 AM ET Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing
3y agoCYTHCyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's DiseaseBusiness Wire– Biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer's disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in CSF, and amyloid plaques in the
3y agoCYTHCyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesBusiness WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for
3y agoCYTHCyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual MeetingBusiness WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
3y agoCYTHCyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesBusiness WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for
4y agoCYTHCyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent AchievementsBusiness Wire– Quarter marked by launch of Phase 2b study of Trappsol® Cyclo™ for the treatment of early Alzheimer's Disease (AD) with patient enrollment and site activation now underway – Building momentum with ongoing
4y agoCYTHCyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)Business Wire– Data published in official journal of the Society for Inherited Metabolic Disorders, Molecular Genetics and Metabolism – Published trial data show that Trappsol® Cyclo™ overcomes the NPC1 defect by
4y agoCYTHCyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's DiseaseBusiness WirePatient enrollment and site activation now underway Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation